Theralase Announces Leadership Transition
20 August 2021 - 6:49AM
Theralase® Technologies Inc. (“
Theralase®” or the
“
Company”) (
TSXV: TLT)
(
OTCQB: TLTFF), a clinical stage pharmaceutical
company dedicated to the research and development of light
activated Photo Dynamic Compounds (“
PDC”) and
associated drug formulations, announced today the departure of its
Chief Executive Officer (“
CEO”), Shawn Shirazi
effective August 20, 2021.
Effective August 23, 2021, John Trikola will
assume the role of Chief Operating Officer (“COO”)
and Interim CEO for the Company. John brings over 25 years of
technology experience working with companies ranging from startups
to global Fortune 500 companies. Most recently, John was the
president of Gardner Ross Corp., where he provided turnaround and
restructuring engagements to various companies in the technology,
manufacturing, and retail sectors.
In addition to his senior management roles, John
currently serves as a Board Director for Waypoint Centre for Mental
Health Care and has served on the Board of Directors and as Chair
of the Fundraising Committee for The Sandbox Project, the Board of
Directors and Governance Committee for the Lougheed House
Conservation Society and as a Mentor and Advisory for the Startup
Community at Innovate Calgary's Alberta Deal Generator.
John stated, “I am honored to join Theralase® as
the COO and Interim CEO. I have developed a deep appreciation for
what makes Theralase® so special and I believe the Company has
tremendous opportunities in front of it to capitalize on the
innovation and technological advancements that the Company has
demonstrated to date. I look forward to working with all
stakeholders to enhance the buyer experience and provide additional
capabilities that will help health care practitioners sustain and
grow their businesses. I will focus on continuing to evolve the
Company's strategy while delivering on Theralase®'s commitment to
maximizing long-term shareholder value.”
Matthew Perraton, Chairman of the Board of
Directors of Theralase® stated, “On behalf of the board of
directors, we thank Shawn for his service as the CEO of the Company
and welcome John to the team. We look forward to working with him
as he brings his extensive experience and knowledge to the Company,
to grow the revenues of the Cool Laser Therapy
(“CLT”) division.
About Theralase® Technologies
Inc.Theralase® is a clinical stage pharmaceutical company
dedicated to the research and development of innovative Anti-Cancer
Therapy (“ACT”) technologies intended to safely
and effectively destroy various cancers, bacteria and viruses,
while preserving patient Quality Of Life
(“QOL”).
Additional information is available at
www.theralase.com and www.sedar.com
Forward Looking Statement:
This news release contains "forward-looking
statements" which reflect the current expectations of the Company's
management for future growth, results of operations, performance,
business prospects and opportunities. Such statements include, but
are not limited to, statements regarding the Company's proposed
development plans with respect to Anti-Cancer Therapy technologies.
Wherever possible, words such as "may",
"would", "could",
"should", "will",
"anticipate", "believe",
"plan", "expect",
"intend", "estimate",
"potential for" and similar expressions have been
used to identify these forward-looking statements. These statements
reflect management's beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions; including, with respect to the ability of the
Company to: adequately fund, secure the requisite regulatory
approvals to commence and successfully complete a Phase II NMIBC
clinical study in a timely fashion and implement its
commercialization plans. Many factors could cause the Company's
actual results, performance or achievements to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements;
including, without limitation, those listed in the filings made by
the Company with the Canadian securities regulatory authorities
(which may be viewed at www.sedar.com). Should one or more of these
risks or uncertainties materialize or should assumptions underlying
the forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in the press release are based upon what management
currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements. The Company disclaims any intention or obligation to
revise forward-looking statements whether as a result of new
information, future developments or otherwise except as required by
law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
1.866.THE.LASE (843.5273)416.699.LASE
(5273)www.theralase.com
Kristina Hachey, CPAChief Financial
Officerkhachey@theralase.com416.699.LASE (5273) x 224
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Aug 2023 to Aug 2024